SGLT-2 inhibitors are beneficial in reducing the risk of thyroid cancer: findings from a Mendelian randomization study.

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM Acta Diabetologica Pub Date : 2024-08-17 DOI:10.1007/s00592-024-02344-8

LiRong Zhang, Jiaqin Cai, Huiting Lin, Wenhua Wu, Congting Hu, Xinmiao Lin, Hong Sun, XiaoXia Wei

{"title":"SGLT-2 inhibitors are beneficial in reducing the risk of thyroid cancer: findings from a Mendelian randomization study.","authors":"LiRong Zhang, Jiaqin Cai, Huiting Lin, Wenhua Wu, Congting Hu, Xinmiao Lin, Hong Sun, XiaoXia Wei","doi":"10.1007/s00592-024-02344-8","DOIUrl":null,"url":null,"abstract":"Objective: Previous studies have investigated the association between diabetes medications and thyroid cancer, but the results have not been conclusive. This study used a Mendelian randomization approach to investigate the causal relationship between diabetes medications and thyroid cancer (TC).Methods: Exposures were six major diabetes medications target, while outcomes were TC and its differentiated forms, including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Mendelian randomization was conducted using IVW, MR-Egger, and weighted median methods. Tests for heterogeneity, horizontal pleiotropy, and leave-one-out were also performed.Results: In European populations, SGLT2 inhibitors were significantly negatively associated with TC (OR 0.051, 95% CI 0.006-0.465, P = 0.0082) as well as PTC (OR 0.034, 95% CI 0.003-0.411, P = 0.0079), while no correlation was found with FTC. These findings remained consistent even after applying the Bonferroni correction.Conclusions: The evidence suggests that SGLT2 inhibitors could be potential therapeutic targets for TC, especially for PTC, in European populations. However, further large-scale randomized controlled trials are necessary to verify their ability to reduce the risk of and treat these types of cancer.","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Diabetologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00592-024-02344-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Previous studies have investigated the association between diabetes medications and thyroid cancer, but the results have not been conclusive. This study used a Mendelian randomization approach to investigate the causal relationship between diabetes medications and thyroid cancer (TC).

Methods: Exposures were six major diabetes medications target, while outcomes were TC and its differentiated forms, including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Mendelian randomization was conducted using IVW, MR-Egger, and weighted median methods. Tests for heterogeneity, horizontal pleiotropy, and leave-one-out were also performed.

Results: In European populations, SGLT2 inhibitors were significantly negatively associated with TC (OR 0.051, 95% CI 0.006-0.465, P = 0.0082) as well as PTC (OR 0.034, 95% CI 0.003-0.411, P = 0.0079), while no correlation was found with FTC. These findings remained consistent even after applying the Bonferroni correction.

Conclusions: The evidence suggests that SGLT2 inhibitors could be potential therapeutic targets for TC, especially for PTC, in European populations. However, further large-scale randomized controlled trials are necessary to verify their ability to reduce the risk of and treat these types of cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SGLT-2抑制剂有利于降低甲状腺癌风险：一项孟德尔随机研究的结果。

研究目的以前曾有研究调查过糖尿病药物与甲状腺癌之间的关系，但结果尚未得出结论。本研究采用孟德尔随机方法调查糖尿病药物与甲状腺癌（TC）之间的因果关系：暴露是六种主要的糖尿病目标药物，结果是甲状腺癌及其分化形式，包括甲状腺乳头状癌（PTC）和甲状腺滤泡癌（FTC）。采用IVW、MR-Egger和加权中值法进行孟德尔随机化。此外，还进行了异质性、水平多向性和leave-one-out检验：在欧洲人群中，SGLT2 抑制剂与 TC（OR 0.051，95% CI 0.006-0.465，P = 0.0082）和 PTC（OR 0.034，95% CI 0.003-0.411，P = 0.0079）显著负相关，而与 FTC 没有相关性。这些结果在应用 Bonferroni 校正后仍保持一致：有证据表明，在欧洲人群中，SGLT2 抑制剂可能是 TC（尤其是 PTC）的潜在治疗目标。然而，有必要进一步开展大规模随机对照试验，以验证其降低罹患和治疗这些类型癌症的风险的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta Diabetologica 医学-内分泌学与代谢

CiteScore

7.30

自引率

2.60%

发文量

180

审稿时长

2 months

期刊介绍： Acta Diabetologica is a journal that publishes reports of experimental and clinical research on diabetes mellitus and related metabolic diseases. Original contributions on biochemical, physiological, pathophysiological and clinical aspects of research on diabetes and metabolic diseases are welcome. Reports are published in the form of original articles, short communications and letters to the editor. Invited reviews and editorials are also published. A Methodology forum, which publishes contributions on methodological aspects of diabetes in vivo and in vitro, is also available. The Editor-in-chief will be pleased to consider articles describing new techniques (e.g., new transplantation methods, metabolic models), of innovative importance in the field of diabetes/metabolism. Finally, workshop reports are also welcome in Acta Diabetologica.